• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆脂蛋白相关磷脂酶 A2 水平升高与冠状动脉慢血流相关。

Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.

机构信息

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, PR China.

Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

出版信息

BMC Cardiovasc Disord. 2020 May 27;20(1):248. doi: 10.1186/s12872-020-01463-8.

DOI:10.1186/s12872-020-01463-8
PMID:32460702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7251718/
Abstract

OBJECTIVE

Coronary slow flow (CSF) is characterized by delayed opacification of distal epicardial coronary arteries without significant coronary stenosis. In addition, The changes of lipoprotein-associated phospholipase A2 (Lp-PLA) as a significant predictive factor for CSF remain controversial. The study aims to investigate the association between plasma Lp-PLA and CSF.

METHODS

In this retrospective study, 170 consecutive patients who underwent coronary angiography were enrolled in Beijing Anzhen Hospital from January 2017 to September 2019, and were divided into CSF group and normal control groups. According to coronary blood flow rate measured by the thrombolysis in myocardial infarction frame count (TFC) method, CSF was defined as TFC > 27. Serum Lp-PLA levels were measured in an enzyme-linked immunosorbent assay.

RESULTS

Lp-PLA levels were higher in the CSF group than in the control group (288.6 ± 50.3 versus 141.9 ± 49.7, P < 0.001) and were significantly correlated with the mean coronary artery thrombolysis in myocardial infarction (TIMI) frame count (r = 0.790, P<0.001). Logistic regression analysis showed that high Lp-PLA was independently associated with CSF after adjustment for conventional risk factors (OR = 1.040, CI = 1.022-1.059, P<0.001). Male sex (OR = 2.192, CI = 1.161-4.140, P = 0.016) and hypertension (OR = 1.965, CI = 1.034-3.736, P = 0.039) were also CSF risk factors. Receiver-operating characteristic curve (ROC) analysis showed that Lp-PLA levels can predict CSF severity; the predictive power was higher than the other risk factors.

CONCLUSION

Our study demonstrated that patients with CSF had higher circulating levels of Lp-PLA than normal controls. After adjustment for potential confounders, increased Lp-PLA was independently associated with presence of CSF.

摘要

目的

冠状动脉慢血流(CSF)的特征是心外膜冠状动脉远端显影延迟,而无明显冠状动脉狭窄。此外,脂蛋白相关磷脂酶 A2(Lp-PLA)作为 CSF 的一个重要预测因子的变化仍存在争议。本研究旨在探讨血浆 Lp-PLA 与 CSF 之间的关系。

方法

本回顾性研究纳入了 2017 年 1 月至 2019 年 9 月在北京安贞医院接受冠状动脉造影的 170 例连续患者,并将其分为 CSF 组和正常对照组。根据心肌梗死溶栓帧数(TFC)法测量的冠状动脉血流速度,将 CSF 定义为 TFC>27。采用酶联免疫吸附试验测定血清 Lp-PLA 水平。

结果

CSF 组 Lp-PLA 水平高于对照组(288.6±50.3 比 141.9±49.7,P<0.001),且与平均冠状动脉 TIMI 帧数呈显著正相关(r=0.790,P<0.001)。多因素 logistic 回归分析显示,在校正传统危险因素后,高 Lp-PLA 与 CSF 独立相关(OR=1.040,CI=1.022-1.059,P<0.001)。男性(OR=2.192,CI=1.161-4.140,P=0.016)和高血压(OR=1.965,CI=1.034-3.736,P=0.039)也是 CSF 的危险因素。受试者工作特征曲线(ROC)分析表明,Lp-PLA 水平可以预测 CSF 的严重程度;其预测能力高于其他危险因素。

结论

本研究表明,CSF 患者的循环 Lp-PLA 水平高于正常对照组。在校正潜在混杂因素后,Lp-PLA 水平升高与 CSF 的存在独立相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/dbc069bebec7/12872_2020_1463_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/f6665a5f7690/12872_2020_1463_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/e65b8de9aa14/12872_2020_1463_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/280af45a6be6/12872_2020_1463_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/c1ae5d2e1d57/12872_2020_1463_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/b31f04adddca/12872_2020_1463_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/dbc069bebec7/12872_2020_1463_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/f6665a5f7690/12872_2020_1463_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/e65b8de9aa14/12872_2020_1463_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/280af45a6be6/12872_2020_1463_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/c1ae5d2e1d57/12872_2020_1463_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/b31f04adddca/12872_2020_1463_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0aa/7251718/dbc069bebec7/12872_2020_1463_Fig6_HTML.jpg

相似文献

1
Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.血浆脂蛋白相关磷脂酶 A2 水平升高与冠状动脉慢血流相关。
BMC Cardiovasc Disord. 2020 May 27;20(1):248. doi: 10.1186/s12872-020-01463-8.
2
The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease.脂蛋白相关磷脂酶 A2 活性与冠状动脉疾病严重程度的关系。
BMC Cardiovasc Disord. 2020 Jun 16;20(1):295. doi: 10.1186/s12872-020-01580-4.
3
Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population.血清Lp-PLA2水平升高与冠状动脉疾病严重程度独立相关:一项中国人群的横断面研究
BMC Cardiovasc Disord. 2015 Feb 26;15:14. doi: 10.1186/s12872-015-0001-9.
4
Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.脂蛋白相关磷脂酶 A2 水平升高对非 ST 段抬高型心肌梗死患者冠状动脉慢血流有预测价值。
Curr Probl Cardiol. 2021 Mar;46(3):100596. doi: 10.1016/j.cpcardiol.2020.100596. Epub 2020 Apr 17.
5
Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.血浆脂蛋白相关磷脂酶A2水平是急性ST段抬高型心肌梗死患者高血栓负荷的独立预测指标。
Int Heart J. 2016 Dec 2;57(6):689-696. doi: 10.1536/ihj.16-011. Epub 2016 Nov 4.
6
Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.脂蛋白相关磷脂酶 A2 在心脏疾病中的作用:不稳定型冠状动脉疾病的潜在早期生物标志物。
Clin Lab. 2020 May 1;66(5). doi: 10.7754/Clin.Lab.2019.190719.
7
Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.年轻成年人中脂蛋白相关磷脂酶A2与斑块负荷/成分的评估。
Coron Artery Dis. 2015 May;26(3):266-71. doi: 10.1097/MCA.0000000000000224.
8
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.脂蛋白相关磷脂酶A2可独立预测冠状动脉疾病的血管造影诊断及冠状动脉性死亡。
Am Heart J. 2006 Nov;152(5):997-1003. doi: 10.1016/j.ahj.2006.01.011.
9
Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.稳定型冠状动脉疾病患者血浆磷脂酶A2浓度与脂蛋白亚组分之间的关系。
Clin Chim Acta. 2015 Jun 15;446:195-200. doi: 10.1016/j.cca.2015.04.032. Epub 2015 Apr 28.
10
Association between the serum lipoprotein-associated phospholipase A level and acute coronary syndrome.血清脂蛋白相关磷脂酶 A 水平与急性冠状动脉综合征的关系。
Cardiovasc J Afr. 2023;34(5):273-277. doi: 10.5830/CVJA-2022-056. Epub 2023 Jan 11.

引用本文的文献

1
Coronary Slow Flow Phenomenon: A Narrative Literature Review.冠状动脉慢血流现象:一篇叙述性文献综述。
Cureus. 2025 Jul 24;17(7):e88657. doi: 10.7759/cureus.88657. eCollection 2025 Jul.
2
Comparison of the Effect of Non-HDL-C/HDL-C Ratio on Coronary Slow Flow with Other Non-Traditional Lipid Markers.非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值对冠状动脉慢血流的影响与其他非传统血脂标志物的比较。
Acta Cardiol Sin. 2024 Jul;40(4):388-401. doi: 10.6515/ACS.202407_40(4).20240419A.
3
Plasma atherogenic indices are independent predictors of slow coronary flow.

本文引用的文献

1
Effects of hyperbaric oxygen on vascular endothelial function in patients with slow coronary flow.高压氧对冠状动脉血流缓慢患者血管内皮功能的影响。
Cardiol J. 2018;25(1):106-112. doi: 10.5603/CJ.a2017.0132.
2
Association of Interleukin-1 Gene cluster polymorphisms with coronary slow flow phenomenon.白细胞介素-1基因簇多态性与冠状动脉慢血流现象的关联
Anatol J Cardiol. 2018 Jan;19(1):34-41. doi: 10.14744/AnatolJCardiol.2017.8071.
3
Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon (CSFP).
血浆致动脉粥样硬化指数是冠状动脉慢血流的独立预测因子。
BMC Cardiovasc Disord. 2021 Dec 20;21(1):608. doi: 10.1186/s12872-021-02432-5.
4
Correlation between Serum LP-PLA2 and sST2 Levels and the Condition of Patients with Acute Heart Failure and Their Prognostic Value.血清脂蛋白磷脂酶A2与可溶性生长刺激表达基因2水平之间的相关性及其在急性心力衰竭患者病情及预后评估中的价值
Evid Based Complement Alternat Med. 2021 Oct 18;2021:8267776. doi: 10.1155/2021/8267776. eCollection 2021.
5
The effect of coronary slow flow on left atrial structure and function.冠状动脉慢血流对左心房结构和功能的影响。
Sci Rep. 2021 Apr 5;11(1):7511. doi: 10.1038/s41598-021-87193-z.
替米沙坦改善冠状动脉慢血流现象(CSFP)中的血管内皮功能障碍。
Cell Biochem Funct. 2018 Jan;36(1):18-26. doi: 10.1002/cbf.3313.
4
Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.在Dimension Vista分析仪上进行脂蛋白相关磷脂酶A2活性测定的性能特征及对意大利健康人群的初步研究。
Biochem Med (Zagreb). 2017 Oct 15;27(3):030701. doi: 10.11613/BM.2017.030701. Epub 2017 Aug 28.
5
Could neutrophil/lymphocyte ratio be an indicator of coronary artery disease, coronary artery ectasia and coronary slow flow?中性粒细胞/淋巴细胞比值能否作为冠状动脉疾病、冠状动脉扩张和冠状动脉血流缓慢的一个指标?
J Int Med Res. 2016 Dec;44(6):1443-1453. doi: 10.1177/0300060516664637. Epub 2016 Nov 10.
6
Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis.动脉粥样硬化中血管壁细胞摄取氧化型低密度脂蛋白的生理学与病理生理学
Vascul Pharmacol. 2016 Sep;84:1-7. doi: 10.1016/j.vph.2016.05.013. Epub 2016 May 30.
7
A novel marker of inflammation in patients with slow coronary flow: lymphocyte-to-monocyte ratio.冠状动脉血流缓慢患者炎症的一种新型标志物:淋巴细胞与单核细胞比值。
Biomark Med. 2016 May;10(5):485-93. doi: 10.2217/bmm-2016-0022. Epub 2016 Apr 18.
8
Coronary Slow Flow Phenomenon Clinical Findings and Predictors.冠状动脉慢血流现象:临床发现与预测因素
Res Cardiovasc Med. 2016 Jan 2;5(1):e30296. doi: 10.5812/cardiovascmed.30296. eCollection 2016 Feb.
9
Plasma PAF-AH (PLA2G7): Biochemical Properties, Association with LDLs and HDLs, and Regulation of Expression.血浆血小板活化因子乙酰水解酶(PLA2G7):生化特性、与低密度脂蛋白和高密度脂蛋白的关联以及表达调控
Enzymes. 2015;38:71-93. doi: 10.1016/bs.enz.2015.09.004. Epub 2015 Oct 17.
10
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).2015年欧洲心脏病学会(ESC)非持续性ST段抬高型急性冠脉综合征患者管理指南:欧洲心脏病学会(ESC)非持续性ST段抬高型急性冠脉综合征患者管理工作组
Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.